FrancophonIA/ELRC3.0 huggingface dataset:
English: The doctor should monitor the patient's blood pressure closely when starting Micardis, and may decide to adjust the patient's blood pressure-lowering medication.
Estonian: Arst peab Micardise ravi alguses tähelepanelikult jälgima patsiendi vererõhku ning ta võib otsustada vererõhku vähendavat annust kohandada.
English: The main measure of effectiveness was the reduction in the number of patients who died or were admitted to hospital, or who had a heart attack or stroke.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide arvu vähenemine, kes surid või vajasid haiglaravi või said infarkti või insuldi.
English: Hypotension may be more common in patients receiving Micardis to prevent cardiovascular problems.
Estonian: Hüpotensioon võib sagedamini esineda patsientidel, kes võtavad Micardist kardiovaskulaarhäirete ennetamiseks.
English: In patients with type 2 diabetes or in patients with moderate or severe kidney impairment, Micardis must also not be used in combination with aliskiren-containing medicines (also used to treat essential hypertension).
Estonian: II tüüpi diabeediga patsiendid või mõõduka kuni raske neerukahjustusega patsiendid ei tohi Micardist kasutada koos aliskireeni sisaldavate ravimitega (samuti essentsiaalse hüpertensiooni ravimid).
English: What is the risk associated with Micardis?
Estonian: Mis riskid Micardisega kaasnevad?
English: Why has Micardis been approved?
Estonian: Miks Micardis heaks kiideti?
English: For more information about treatment with Micardis, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Micardisega toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: For the prevention of cardiovascular problems, 80 mg Micardis once a day has been studied in one main study involving almost 26,000 patients aged 55 years or over who had heart or artery disease, had had a stroke, or had diabetes and were at high risk of cardiovascular problems.
Estonian: Kardiovaskulaarhäirete ennetamiseks uuriti üks kord ööpäevas manustatava 80 mg Micardise annuse mõju ühes põhiuuringus, milles osales ligikaudu 26 000 vähemalt 55-aastast patsienti, kellel oli südame- või arterite haigus, oli olnud infarkt või kellel oli diabeet ja kardiovaskulaarhäirete suur risk.
English: Micardis was compared with ramipril (another medicine to prevent cardiovascular problems), and with the combination of both medicines.
Estonian: Micardise toimet võrreldi ramipriili toimega (samuti kardiovaskulaarhäirete ennetamise ravim) ja mõlema ravimi koostoimega.
English: For the treatment of essential hypertension, the usual recommended dose of Micardis is 40 mg once a day, but some patients may benefit from using 20 mg once a day.
Estonian: Essentsiaalse hüpertensiooni raviks on tavaline soovitatav Micardise annus 40 mg üks kord ööpäevas, kuid mõnele patsiendile võib piisata ka annusest 20 mg üks kord ööpäevas.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Micardis, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Micardise omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).
Estonian: Efektiivsuse põhinäitaja oli diastoolse vererõhu (kahe südamelöögi vaheline ehk nn alumine vererõhk) alanemine.
English: Various doses of Micardis were compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Estonian: Micardise eri annuste toimet võrreldi platseebo (näiva ravimi) ja teiste kõrgvererõhuravimite (atenolool, lisinopriil, enalapriil, amlodipiin) toimega.
English: The active substance in Micardis, telmisartan, is an ‘angiotensin II receptor antagonist', which means that it blocks the action of a hormone in the body called angiotensin II.
Estonian: Micardise toimeaine telmisartaan on angiotensiin II retseptori antagonist, mis blokeerib organismi hormooni angiotensiin II toime.
English: This allows the blood pressure to drop, reducing the risks associated with high blood pressure, such as having a heart attack or stroke.
Estonian: See vähendab vererõhku ja kõrgvererõhuga seotud riske, näiteks infarkti või insuldi riski.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Micardis.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In the prevention of cardiovascular problems, Micardis had a similar effect to ramipril, with around 17% of patients dying, being admitted to hospital because of cardiovascular problems, or having a heart attack or stroke.
Estonian: Kardiovaskulaarhäirete ennetamisel sarnanes Micardise toime ramipriili toimega: ligikaudu 17% patsientidest suri, vajas kardiovaskulaarhäirete tõttu haiglaravi või sai südameinfarkti või insuldi.
English: For the full list of all side effects reported with Micardis, see the package leaflet.
Estonian: Micardise kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Micardis must not be used in people who have severe liver problems or bile problems.
Estonian: Micardist ei tohi kasutada ka patsiendid, kellel on rasked maksa- või sapihäired.
English: For the prevention of cardiovascular problems, the recommended dose is 80 mg once a day.
Estonian: Kardiovaskulaarhäirete ennetamiseks on soovitatav annus 80 mg üks kord ööpäevas.
English: Micardis must not be used in women who are more than three months pregnant.
Estonian: Micardist ei tohi kasutada rasedad pärast esimest kolme raseduskuud.
English: For the treatment of essential hypertension, Micardis has been studied in 2,647 patients who took Micardis either alone or in combination with hydrochlorothiazide.
Estonian: Essentsiaalse hüpertensiooni ravis uuriti Micardist 2647 patsiendil, kes võtsid kas ainult Micardist või Micardist koos hüdroklorotiasiidiga.
English: Angiotensin II is a powerful vasoconstrictor (a substance that narrows blood vessels).
Estonian: Angiotensiin II on tugeva toimega vasokonstriktor (veresooni ahendav aine).
English: In the treatment of essential hypertension, Micardis was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Estonian: Essentsiaalse hüpertensiooni ravis oli Micardis diastoolse vererõhu vähendamisel efektiivsem kui platseebo ning ravimi toime kõrgvererõhule sarnanes teiste kõrgvererõhuravimite toimega.
English: Patients with mild or moderately reduced liver function should not receive doses higher than 40 mg a day.
Estonian: Maksa kerge või mõõduka talitlushäirega patsiendid ei tohi kasutada suuremaid annuseid kui 40 mg üks kord ööpäevas.
English: Micardis is used to treat essential hypertension (high blood pressure) in adults.
Estonian: Micardist kasutatakse essentsiaalse hüpertensiooni (kõrgvererõhutõve) ravimiseks täiskasvanud patsientidel.
English: Micardis is also used to prevent cardiovascular problems (problems with the heart and blood vessels) such as heart attacks or strokes.
Estonian: Micardist kasutatakse ka kardiovaskulaarsete (südame-veresoonkonna) häirete, näiteks infarkti või insuldi ennetamiseks.
English: Side effects with Micardis are not common.
Estonian: Micardise kasutamisel esineb kõrvalnähte harva.
English: How does Micardis work?
Estonian: Kuidas Micardis toimib?
English: What is Micardis used for?
Estonian: Milleks Micardist kasutatakse?
English: What benefit has Micardis shown during the studies?
Estonian: Milles seisneb uuringute põhjal Micardise kasulikkus?
English: Patients with severely reduced kidney function should receive a lower starting dose of 20 mg once a day.
Estonian: Neeru raske talitlushäirega patsiendid peavad alustama ravi annusega 20 mg üks kord ööpäevas.
English: How is Micardis used?
Estonian: Kuidas Micardist kasutatakse?
English: How has Micardis been studied?
Estonian: Kuidas Micardist uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Micardis on retseptiravim.
English: It is available as capsules (50 and 150 mg).
Estonian: Seda turustatakse kapslitena (50 ja 150 mg).
English: This summary was last updated in 07-2013.
Estonian: Kokkuvõtte viimane uuendus: 07-2013.
English: The body is able to remove this salt from the cells.
Estonian: Organism suudab seda soola rakkudest eemaldada.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Cystagon on 23 June 1997.
Estonian: Euroopa Komisjon andis Cystagoni müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 23. juunil 1997.
English: The starting dose should be increased gradually over 4 to 6 weeks.
Estonian: Algannust suurendatakse järk-järgult 4-6 nädala jooksul.
English: The full EPAR for Cystagon can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Cystagoni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: Cystagon has been investigated in three main studies including 234 patients over a 12-year period.
Estonian: Cystagoni uuriti kolmes kliinilises põhiuuringus, milles osales 12 aasta vältel 234 patsienti.
English: The maximum dose should never exceed 1.95 g per m2 per day.
Estonian: Maksimaalne annus ei tohi mingil juhul ületada annust 1,95 g/m2 ööpäevas.
English: Cystagon mercaptamine
Estonian: Cystagon merkaptamiin
English: The three studies showed that Cystagon delays kidney problems and the need for dialysis or renal transplantation, when treatment is started at an early age.
Estonian: Kolmes uuringus selgus, et ravi Cystagoniga lükkab edasi neeruprobleemide tekkimist ning neeru dialüüsi või siirdamise vajadust, kui ravi algab varajases eas.
English: The amount of cystine in the organs is therefore reduced, and this limits the damage to these organs.
Estonian: See vähendab tsüstiini kogust elundites, mis vähendab nende elundite kahjustusi.
English: Starting doses should be one quarter to one sixth of the final expected doses.
Estonian: Algannus peab olema 1/4...1/6 eeldatavast lõplikust annusest.
English: It should also not be used in women who are breastfeeding, or who are pregnant (particularly during the first three months) unless it is clearly necessary.
Estonian: Ravimit ei tohi kasutada imetamise ega raseduse ajal (eriti kolme esimese raseduskuu vältel), v.a kui ravi järgi on ilmne vajadus.
English: It also improves survival and growth rate in the children treated.
Estonian: See suurendab ka ravitavate laste elulemust ja kasvukiirust.
English: This is a summary of the European public assessment report (EPAR) for Cystagon.
Estonian: See on ravimi Cystagon Euroopa avaliku hindamisaruande kokkuvõte.
English: For children up to the age of 12 years, the recommended daily dose is calculated according to body surface area (which is calculated from the patient's height and weight), as 1.30 g per m2 divided into 4 doses.
Estonian: Kuni 12-aastaste laste soovitatav ööpäevane annus arvutatakse kehapindala järgi (mis omakorda arvutatakse patsiendi pikkuse ja kaalu järgi) ja on 1,30 g/m2 jagatuna 4 manustamiskorrale.
English: The CHMP decided that Cystagon's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Cystagoni kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Other information about Cystagon
Estonian: Muu teave Cystagoni kohta
English: These studies included children and newly recruited patients in whom two different doses were tested.
Estonian: Uuringutes osalesid lapsed ja uued patsiendid, kellel uuriti kahe annuse toimet.
English: For more information about treatment with Cystagon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Cystagoniga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Because the disease is very serious, it was not possible for ethical reasons to compare Cystagon directly to placebo (a dummy treatment).
Estonian: Et haigus on väga raske, ei olnud eetikapõhjustel võimalik otseselt võrrelda Cystagoni mõju platseeboga (näiva ravimiga).
English: The studies looked at the kidney function, the survival and the growth rate of the patients.
Estonian: Uuringutes jälgiti patsientide neerutalitlust, elulemust ja kasvukiirust.
English: Cystinosis is a rare, fatal disease, and Cystagon is considered a useful medicine for this disease.
Estonian: Tsüstinoos on haruldane ja fataalne haigus, mille ravis peetakse Cystagoni kasulikuks.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Cystagon.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: For patients over the age of 12 and over 50 kg in weight, the recommended daily dose is 2 g divided into 4 doses.
Estonian: Üle 12aastastele ja üle 50 kg kaaluvate patsientide soovitatav ööpäevane annus on 2 g jagatuna 4 annustamiskorrale.
English: Cystagon must not be used in people who are hypersensitive (allergic) to cysteamine or any of the other ingredients, or to another medicine called penicillamine.
Estonian: Cystagoni ei tohi kasutada patsiendid, kes on tsüsteamiini, selle ravimi mis tahes muu koostisaine või penitsillamiini suhtes ülitundlikud (allergilised).
English: What is Cystagon?
Estonian: Mis on Cystagon?
English: Why has Cystagon been approved?
Estonian: Miks Cystagon heaks kiideti?
English: The most common side effects with Cystagon (seen in more than 1 patient in 10) are loss of appetite, vomiting, nausea (feeling sick), diarrhoea, lethargy (lack of energy) and pyrexia (fever).
Estonian: Cystagoni kõige sagedamad kõrvalnähud (esinenud 1-10 patsiendil 100st) on isutus, oksendamine, peavalu, iiveldus, kõhulahtisus, loidus ja palavik.
English: What is the risk associated with Cystagon?
Estonian: Mis riskid Cystagoniga kaasnevad?
English: For the full list of all side effects reported with Cystagon, see the package leaflet.
Estonian: Cystagoni kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Cystagon is a medicine containing the active substance mercaptamine (also known as cysteamine).
Estonian: Cystagon on ravim, mis sisaldab toimeainena merkaptamiini (teise nimetusega tsüsteamiin).
English: Cystinosis is a rare inherited disease in which excess amounts of cystine, an amino acid naturally found in the body, build up within cells, especially in the kidneys and the eyes, damaging them.
Estonian: Tsüstinoos on haruldane pärilik haigus, mille korral koguneb rakkudesse, eelkõige neeru- ja silmarakkudesse normaalsest rohkem tsüstiini.
English: The active substance in Cystagon, mercaptamine, reacts with cystine to form another amino acid, called cysteine, and a compound called a cysteine-cysteamine salt.
Estonian: Cystagoni toimeaine merkaptamiin reageerib tsüstiiniga, mille tulemusena tekib aminohape tsüsteiin ning tsüsteiini ja tsüsteamiini sool.
English: Cystagon treatment should be started by a doctor who has experience in the treatment of cystinosis.
Estonian: Ravi Cystagoniga tohib alustada üksnes tsüstinoosi ravis kogenud arst.
English: Cystine levels in white blood cells should be monitored and used to adjust the dose.
Estonian: Ravi ajal tuleb jälgida leukotsüütide (vere valgeliblede) tsüsteiinisisaldust ja annust kohandada.
English: How does Cystagon work?
Estonian: Kuidas Cystagon toimib?
English: What benefit has Cystagon shown during the studies?
Estonian: Milles seisneb uuringute põhjal Cystagoni kasulikkus?
English: What is Cystagon used for?
Estonian: Milleks Cystagoni kasutatakse?
English: Cystagon is used in patients who have nephropathic (kidney) cystinosis.
Estonian: Cystagoni kasutatakse nefropaatilise (neerude) tsüstinoosiga patsientide ravimiseks.
English: The comparison was done instead with a group of patients who had been treated with a dummy treatment as part of another, unrelated trial.
Estonian: Võrdlusena kasutati patsiendirühma, kes oli võtnud platseebot muu, Cystagoni uuringutega mitteseotud uuringu osana.
English: How is Cystagon used?
Estonian: Kuidas Cystagoni kasutatakse?
English: How has Cystagon been studied?
Estonian: Kuidas Cystagoni uuriti?
English: The medicine can only be obtained with a prescription.
Estonian: Cystagon on retseptiravim.
English: In such cases, the Western Blot method is negative.
Estonian: Sellistel juhtudel on Western Blot meetod negatiivne.
English: 7.5 micrograms**
Estonian: 7,5 mikrogrammi**
English: CZ-281 63 Kostelec nad Cernymi lesy Czech Republic
Estonian: CZ-281 63 Kostelec nad Cernymi lesy Tšehhi Vabariik
English: All subjects
Estonian: Kõik subjektid
English: SPECIAL STORAGE CONDITIONS Store in refrigerator.
Estonian: SÄILITAMISE ERITINGIMUSED Hoida külmkapis.
English: After first opening, the product should be used immediately.
Estonian: Pärast esmast avamist tuleb toodet kasutada kohe.
English: • you have a severe infection with a high temperature (over 38 °C).
Estonian: • kui teil on raske nakkus, millega kaasneb kõrge palavik (üle 38 °C).
English: In the first few weeks after vaccination with Celvapan the results of these tests may not be correct.
Estonian: Esimese paari nädala jooksul pärast vaktsineerimist Celvapan'iga ei pruugi nende testide tulemused olla õiged.
English: Ask your pharmacist what to do with medicines you no longer use.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida te enam ei kasuta.
English: For further information, see sections 4.8 and 5.1.
Estonian: Lisainformatsiooni vt lõik 4.8 ja 5.1.
English: Please tell your doctor or nurse if you are taking or have recently taken any other medicines, including medicines obtained without a prescription or have recently been given any other vaccine.
Estonian: Palun informeerige oma arsti või meditsiiniõde, kui te kasutate või olete hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid, või kui olete hiljuti saanud mõnda muud vaktsiini.
English: Preferred MedDRA Term
Estonian: Eelistuslik MedDRA termin
English: Dispose of in accordance with local requirements.
Estonian: Hävitada vastavalt kohalikele nõuetele.
English: Shake before use.
Estonian: Enne kasutamist raputada.
English: The frequency of these adverse reactions is not known.
Estonian: Nende kõrvaltoimete esinemissagedus ei ole teada.
English: Store in a refrigerator (2 °C - 8 °C).
Estonian: Hoida külmkapis (2 °C…8 °C).
English: Other medicines and Celvapan
Estonian: Muud ravimid ja Celvapan
English: Day 181
Estonian: 181. päev
English: The safety of Celvapan in pregnancy and lactation has been assessed in a limited number of pregnant
Estonian: Celvapan'i ohutust raseduse ja imetamise ajal on hinnatud piiratud hulgal rasedatel.
English: If this applies to you then your vaccination will usually be postponed until you are feeling better.
Estonian: Kui see on nii, lükatakse vaktsineerimine edasi, kuni te tunnete end paremini.
English: However, some differences in frequency and type of side effects were observed.
Estonian: Siiski esines erinevusi sageduses ja kõrvaltoimete tüüpides.
English: • Safety and immunogenicity data in healthy adults, including older people.
Estonian: • ohutuse ja immunogeensuse andmed tervetel täiskasvanutel, sealhulgas vanematel inimestel.
English: Results from Vaccine Effectiveness Study in Jersey
Estonian: Jersey's tehtud vaktsiini tõhusust hindava uuringu tulemused
English: Pharmacotherapeutic group: Influenza vaccines, ATC Code J07BB01
Estonian: Farmakoterapeutiline grupp: gripivaktsiinid, ATC kood J07BB01
English: 18 to 59 years
Estonian: 18 kuni 59 aastat
English: Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu/.
Estonian: Täpne informatsioon selle ravimi kohta on kättesaadav Euroopa Ravimiameti (EMA) kodulehel http://www.ema.europa.eu.
English: DATE OF FIRST AUTHORISATION / RENEWAL OF THE AUTHORISATION
Estonian: ESMASE MÜÜGILOA VÄLJASTAMISE / MÜÜGILOA UUENDAMISE KUUPÄEV
English: For storage conditions after first opening of the medicinal product, see section 6.3.
Estonian: Säilitamistingimused pärast ravimpreparaadi esmast avamist vt lõik 6.3.
English: Justification for not including Braille accepted.
Estonian: INFORMATSIOON BRAILLE' KIRJAS (PUNKTKIRJAS) Põhjendus Braille mitte lisamiseks on aktsepteeritud.
English: • Safety and immunogenicity data obtained three weeks after administration of two doses of
Estonian: • Immunogeensuse ja ohutusandmed, mis on saadud kolm nädalat pärast kahe doosi Celvapani
English: 3 to 8 years
Estonian: 3-8 aastat
English: In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal
Estonian: Sobivusuuringute puudumisel ei tohi seda ravimpreparaati teiste ravimitega segada.
English: Day 361
Estonian: 361. päev
English: Read all of this leaflet carefully before you receive this vaccine because it contains important information for you.
Estonian: Enne vaktsineerimist lugege hoolikalt infolehte, sest siin on teile vajalikku teavet.
English: Such reactions have occurred both in patients with a history of multiple allergies and in patients with no known allergy.
Estonian: Selliseid reaktsioone on esinenud nii multiallergilistel patsientidel kui ka patsientidel, kellel teadaolevalt pole ühtegi allergiat.
English: • you are having a blood test to look for evidence of infection with certain viruses.
Estonian: • kui teile tehakse vereanalüüse, mis viitavad infektsioonile teatud viirustega.
English: The immunological response may be diminished if the patient is undergoing immunosuppressant treatment.
Estonian: Immuunvastus võib olla nõrgem, kui patsient saab immunosupressiivset ravi.
English: • you have problems with your immune system, since your response to the vaccine may then be poor.
Estonian: • kui teil on immuunsüsteemihäired, sest võite vaktsiinile halvasti reageerida.
English: In accordance with Article 114 Directive 2001/83/EC, the official batch release will be undertaken by a state laboratory or a laboratory designated for that purpose.
Estonian: • Ravimipartii ametlik kasutamiseks vabastamine Vastavalt direktiivi 2001/83/EÜ artiklile 114 toimub ravimipartii ametlik kasutamiseks vabastamine riikliku laboratooriumi või selleks eesmärgiks määratud laboratooriumi poolt.
English: 6.5 Nature and contents of the container
Estonian: 6.5 Pakendi iseloomustus ja sisu
English: 21 Days After
Estonian: 21 päeva hiljem21 päeva hiljem
English: Possible side effects Like all medicines, Celvapan can cause side effects, although not everybody gets them.
Estonian: Nagu kõik ravimid, võib ka Celvapan põhjustada kõrvaltoimeid, kuigi kõigil neid ei teki.
English: Frequency 9 - 17 years 3 - 8 years 6 - 35 months
Estonian: Sagedus 9-17 aastat 3-8 aastat 6-35 kuud
English: OTHER SPECIAL WARNING(S), IF NECESSARY Do not inject intravascularly.
Estonian: TEISED ERIHOIATUSED (VAJADUSEL) Mitte süstida veresoonde.
English: Your doctor or nurse will administer the vaccine in accordance with official recommendations.
Estonian: Vaktsiini manustab arst või meditsiiniõde vastavalt ametlikele juhistele.
English: Your doctor will discuss with you whether you should be given Celvapan.
Estonian: Arst arutab teiega, kas teile tuleks Celvapan'i süstida.